In this episode, we explore sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Did you know that women are less likely to receive a CKD diagnosis, visit a nephrologist, or access guideline-recommended therapies—even in developed countries?
To help us unpack these critical issues, we're joined by Professor Adeera Levin, Head of the Division of Nephrology at the University of British Columbia in Canada
Together, we’ll discuss the biological, societal, and systemic barriers driving these disparities and, more importantly, how we can overcome them. 

Today, we address a crucial and evolving topic: the Approach to Conservative Care for ESKD Patients. This area has garnered increasing attention at national and international levels, reflecting the need for better detection, diagnosis, and therapeutic strategies tailored to this growing patient population.
We’re joined by Prof. Holly Koncicki, Associate Professor at Mount Sinai Health System, New York, USA, who will help us explore whether conservative care could be considered a legitimate therapeutic option for ESKD, how do we define and engage the target population and what tools and approaches can optimize conservative care delivery.

We’ve probably all noticed that our nurses have a different perspective of our patients than the one we do ourselves and maybe we can say that often their perspective is closer to what the patient is feeling, so it’s definitely a fresh outlook. We will be talking about this with Jeanette Finderup in our episode on the nurse’s perspective, where you can expect to hear about what she thinks the role of the nurse is, what she thinks the role of the nurse is not, and how we could collaborate for the benefit of our patients to provide them with the most comprehensive healthcare that we can. 

You’ve probably all heard about Imlifidase, the new miracle drug which is capable of bringing down IgG from normal levels to virtually zero in a matter of hours. Is this going to be a revolution in transplantation, particularly for allosensitized patients? You can get the answers to these questions by listening to our podcast with Rainer Oberbauer on Imlifidase. You can expect to hear how the drug works, how well it performs, particularly in allosensitized individuals, and what are the tips and tricks for using this drug. 

In this ANCA vasculitis episode we will be talking to Vladimir Tesar about the new KDIGO guidelines – what are the novelties, how we should treat ANCA vasculitis patients in this day and age, some difficult cases will be discussed, plasma exchange, rituximab, and much, much more.

In this episode, we explore the latest insights on treating arterial hypertension in 2025. With updates from the European Society of Hypertension and the European Society of Cardiology, the standards for blood pressure management are evolving rapidly.
Joining us is Pantelis Sarafidis from Aristotle University of Thessaloniki. What’s new in these guidelines? How do they redefine hypertension management, particularly for patients with kidney disease? And what does the treatment algorithm look like for 2025 and beyond?